🇺🇸 FDA
Patent

US 9744235

Treatment of cardiovascular disorders with targeted nanoparticles

granted A61KA61K33/06A61K41/00

Quick answer

US patent 9744235 (Treatment of cardiovascular disorders with targeted nanoparticles) held by The Board of Regents of the University of Oklahoma expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue Aug 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K33/06, A61K41/00, A61K9/0009, A61K9/0019